Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-18T12:49:15.417Z Has data issue: false hasContentIssue false
  • English
  • Français

Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression

Part of: EPA Guidance Papers

Published online by Cambridge University Press:  15 April 2020

H.-J. Möller ,
I. Bitter ,
J. Bobes ,
K. Fountoulakis ,
C. Höschl  and
S. Kasper
H.-J. Möller*
Affiliation:
Department of Psychiatry, Ludwig-Maximilians-University, Nussbaumstrasse 7, 80336Munich, Germany
I. Bitter
Affiliation:
Department of Psychiatry and Psychotherapy, Semmelweis University of Medicine, Balassa u6, 1083Budapest, Hungary
J. Bobes
Affiliation:
Department of Psychiatry, School of Medicine, University of Oviedo. CIBERSAM, Julian Clavería 6, 3°, 33006Oviedo, Spain
K. Fountoulakis
Affiliation:
Third Department of Psychiatry, Aristotle University of Thessaloniki, 1 Kyriakidi str, UH, AHEPA, Thessaloniki, Greece
C. Höschl
Affiliation:
Psychiatric Centre Prague, 3rd Medical Faculty, Charles University, Ustavni 91, 181 03Prague 8-Bohnice, Czech Republic
S. Kasper
Affiliation:
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Gürtel 18-20, A-1090Vienna, Austria
*
*Corresponding author. Tel.: +49 89 5160 5501; fax: +49 89 5160 5522. ?E-mail address:[email protected] (H.-J. Möller).
Get access

Abstract

This position statement will address in an evidence-based approach some of the important issues and controversies of current drug treatment of depression such as the efficacy of antidepressants, their effect on suicidality and their place in a complex psychiatric treatment strategy including psychotherapy. The efficacy of antidepressants is clinically relevant. The highest effect size was demonstrated for severe depression. Based on responder rates and based on double-blind placebo-controlled studies, the number needed to treat (NNT) is 5–7 for acute treatment and four for maintenance treatment. Monotherapy with one drug is often not sufficient and has to be followed by other antidepressants or by comedication/augmentation therapy approaches. Generally, antidepressants reduce suicidality, but under special conditions like young age or personality disorder, they can also increase suicidality. However, under the conditions of good clinical practice, the risk–benefit relationship of treatment with antidepressants can be judged as favourable also in this respect. The capacity of psychiatrists to individualise and optimise treatment decisions in terms of ‘the right drug/treatment for the right patient’ is still restricted since currently there are no sufficient powerful clinical or biological predictors which could help to achieve this goal. There is hope that in future pharmacogenetics will contribute significantly to a personalised treatment. With regard to plasma concentration, therapeutic drug monitoring (TDM) is a useful tool to optimize plasma levels therapeutic outcome. The ideal that all steps of clinical decision-making can be based on the strict rules of evidence-based medicine is far away from reality. Clinical experience so far still has a great impact.

Keywords

AntidepressantsDepression treatmentEfficacySuicidalityReview
Type
Original article
Information
European Psychiatry , Volume 27 , Issue 2 , February 2012 , pp. 114 - 128
Copyright
Copyright © Elsevier Masson SAS 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adli, M., Bauer, M., Rush, A.J.Algorithms and collaborative care systems for depression: are they effective and why?. Biol Psychiatry. 2006; 59: 1029–1038CrossRefGoogle Scholar
Adli, M., Berghöfer, A., Linden, M., Helmchen, H., Müller-Oerlinghausen, B., Mackert, A., et al.Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J Clin Psychiatry. 2002; 63(9): 782–790CrossRefGoogle ScholarPubMed
Alonso, J., Angermeyer, M.C., Bernert, S., Bruffaerts, R., Brugha, T.S., Bryson, H., et al.Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004; 420: 21–27Google Scholar
American Psychiatric Association. APA Practice Guidelines - treatment of patients with major depressive disorder, Second Edition. http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_7.aspx [Second]. 2000. [Ref Type: Electronic Citation].Google Scholar
Anderson, I.M.Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000; 58(1): 19–36CrossRefGoogle ScholarPubMed
Anderson, I.M., Ferrier, I.N., Baldwin, R.C., Cowen, P.J., Howard, L., Lewis, G., et al.Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008; 22(4): 343–396CrossRefGoogle ScholarPubMed
Angst, J., Angst, F., Gerber-Werder, R., Gamma, A.Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years’ follow-up. Arch Suicide Res. 2005; 9(3): 279–300CrossRefGoogle Scholar
Angst, J., Gamma, A., Sellaro, R., Zhang, H., Merikangas, K.Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord. 2002; 72(1): 125–138CrossRefGoogle ScholarPubMed
Baghai, T.C., Volz, H.P., Moller, H.J.Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry. 2006; 7(4): 198–222CrossRefGoogle ScholarPubMed
Balazs, J., Benazzi, F., Rihmer, Z., Rihmer, A., Akiskal, K.K., Akiskal, H.S.The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord. 133; 91(2–3–2006): 132–3Google Scholar
Baldwin, D., Broich, K., Fritze, J., Kasper, S., Westenberg, H., Möller, H.J.Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci. 2003; 253: 22–28CrossRefGoogle ScholarPubMed
Barbui, C., Campomori, A., D’Avanzo, B., Negri, E., Garattini, S.Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol. 1999; 34(3): 152–156CrossRefGoogle ScholarPubMed
Bauer, M., Bschor, T., Pfennig, A., Whybrow, P.C., Angst, J., Versiani, M., et al.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007; 8(2): 67–104CrossRefGoogle ScholarPubMed
Bauer, M., Tharmanathan, P., Volz, H.P., Moeller, H.J., Freemantle, N.The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2009; 259(3): 172–185CrossRefGoogle ScholarPubMed
Bauer, M, Whybrow, PC, Angst, J, Versiani, M, Möller, HJ, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3:5–43 [Ref Type: Journal (Full)].CrossRefGoogle ScholarPubMed
Bauer, M.S., Wisniewski, S.R., Marangell, L.B., Chessick, C.A., Allen, M.H., Dennehy, E.B., et al.Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry. 2006; 67(1): 48–55CrossRefGoogle Scholar
Bech, P.Depressive symptomatology and drug response. Commun Psychopharmacol. 1978; 2(5): 409–418Google ScholarPubMed
Bech, P.Is the antidepressive effect of second-generation antidepressants a myth?. Psychol Med. 2009 16Google Scholar
Belmaker, R.H., Agam, G.Major depressive disorder. N Engl J Med. 2008; 358(1): 55–68CrossRefGoogle ScholarPubMed
Benazzi, F., Akiskal, H.S.How best identify to a bipolar-related subtype among major depressive patients without spontaneous hypomania: superiority of age at onset criterion over recurrence and polarity?. J Affect Disord. 2008.107(1–3): 77–88CrossRefGoogle ScholarPubMed
Brent, D.A.Antidepressants and pediatric depression - the risk of doing nothing. N Engl J Med. 2004; 351: 1598–1601Google ScholarPubMed
Bschor, T., Berghöfer, A., Ströhle, A., Kunz, D., Adli, M., Müller-Oerlinghausen, B., et al.How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol. 2002; 22(4): 427–430CrossRefGoogle ScholarPubMed
Caspi, A., Moffitt, T.E.Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci. 2006; 7(7): 583–590CrossRefGoogle ScholarPubMed
Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P., Churchill, R., et al.Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665): 746–758CrossRefGoogle ScholarPubMed
Crossley, N.A., Bauer, M.Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007; 68(6): 935–940CrossRefGoogle ScholarPubMed
Cuijpers, P., van Straten, A., Warmerdam, L.Behavioral activation treatments of depression: a meta-analysis. Clin Psychol Rev. 2007; 27(3): 318–326CrossRefGoogle ScholarPubMed
de Maat, S., Dekker, J., Schoevers, R., van Aalst, G., Gijsbers-van Wijk, C., Hendriksen, M., et al.Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: a mega-analysis based on three randomized clinical trials. Depress Anxiety. 2008; 25(7): 565–574CrossRefGoogle ScholarPubMed
Deutsche Gesellschaft für Psychiatrie PuN. S3-Leitlinien/Nationale VersorgungsLeitlinie Unipolare Depression. In: DGPPN, BÄK, KBV, AWMF, AkdÄ B, BApK et al., editors. 2009. Berlin, Düsseldorf, Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde.Google Scholar
Drago, A., De Ronchi, D., Serretti, A.Pharmacogenetics of antidepressant response: an update. Hum Genomics. 2009; 3(3): 257–274CrossRefGoogle ScholarPubMed
European Medicines Agency Press Office. European Medicines Agency finalises review of antidepressants in children and adolescents. http://www.ema.europa.eu/pdfs/human/press/pr/12891805en.pdf. 2005 Ref Type: Internet Communication.Google Scholar
Fava, G.A., Grandi, S., Zielezny, M., Canestrari, R., Morphy, M.A.Cognitive behavioural treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry. 1994; 151: 1295–1299Google ScholarPubMed
Fava, G.A., Grandi, S., Zielezny, M., Rafanelli, C., Canestrari, R.Four-year outcome for cognitive behavioural treatment of residual symptoms in major depression. Am J Psychiatry. 1996; 153: 945–947Google ScholarPubMed
Fava, G.A., Rafanelli, C., Grandi, S., Canestrari, R., Morphy, M.A.Six year outcome for cognitive behavioural treatment of residual symptoms in major depression. Am J Psychiatry. 1998; 155: 1443–1445CrossRefGoogle ScholarPubMed
Fergusson, D., Doucette, S., Glass, K.C., Shapiro, S., Healy, D., Hebert, P., et al.Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 33074882005 396CrossRefGoogle ScholarPubMed
Fountoulakis, KN, Möller, HJEfficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 2011;14(3):405–12.CrossRefGoogle ScholarPubMed
Fournier, J.C., DeRubeis, R.J., Hollon, S.D., Dimidjian, S., Amsterdam, J.D., Shelton, R.C., et al.Antidepressant drug effects and depression severity. A patient-level meta-analysis. JAMA. 2010; 303(1): 47–53CrossRefGoogle ScholarPubMed
Frank, E., Kupfer, D., Perel, J., Cornes, C., Jarrett, D., Mallinger, A.Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990; 47: 1093–1099CrossRefGoogle ScholarPubMed
Frey, R., Schreinzer, D., Stimpfl, T., Vycudilik, W., Berzlanovich, A., Kasper, S.Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991–1997: the favourable consequences of the increasing use of SSRIs. Eur Neuropsychopharmacol. 2000; 10: 133–142CrossRefGoogle ScholarPubMed
Friedman, M.A., Detweiler-Bedell, J.B., Leventhal, H.W., Horne, R., Keitner, G.I., Miller, I.W.Combined psychotherapy and pharmacotherapy for the treatment of depression disorder. Clin Psychol Sci Pract. 2004; 11: 47–68CrossRefGoogle Scholar
Fritze, J., Möller, H.J.Design of clinical trials of antidepressants. Should a placebo control arm be included?. CNS Drugs. 2001; 15(10): 755–764[Ref Type: Journal (Full)]CrossRefGoogle Scholar
Frodl, T., Meisenzahl, E.M., Zill, P., Baghai, T., Rujescu, D., Leinsinger, G., et al.Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry. 2004; 61(2): 177–183CrossRefGoogle Scholar
Frodl, T., Moller, H.J., Meisenzahl, E.Neuroimaging genetics: new perspectives in research on major depression?. Acta Psychiatr Scand. 2008; 118(5): 363–372CrossRefGoogle ScholarPubMed
Fulford, K.W.M.Facts/values: ten principles of value-based medicine. Radden, J.The philosophy of psychiatry: a companion. New York: Oxford University Press; 2004Google Scholar
Geddes, J.R., Carney, S.M., Davies, C., Furukawa, T.A., Kupfer, D.J., Frank, E., et al.Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003; 361(9358): 653–661CrossRefGoogle ScholarPubMed
Geddes, J.R., Cipriani, A.Selective serotonin reuptake inhibitors. BMJ. 2004; 329(7470): 809–810CrossRefGoogle ScholarPubMed
Gibbons, R.D., Brown, C.H., Hur, K., Marcus, S.M., Bhaumik, D.K., Erkens, J.A., et al.Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007; 164(9): 1356–1363CrossRefGoogle ScholarPubMed
Goodwin, G.M., Emsley, R., Rembry, S., Rouillon, F.Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(8): 1128–1137CrossRefGoogle ScholarPubMed
Grunebaum, M.F., Ellis, S.P., Li, S., Oquendo, M.A., Mann, J.J.Antidepressants and sucide risk in the United States, 1985–1999. J Clin Psychiatry. 2004; 65(1): 1456–1462CrossRefGoogle Scholar
Grunze, H., Vieta, E., Goodwin, G.M., Bowden, C., Licht, R.W., Möller, H.J., et al.The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010; 11(2): 81–109CrossRefGoogle ScholarPubMed
Guaiana, G., Andretta, M., Corbari, L., Mirandola, M., Sorio, A., D’Avanzo, B., et al.Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. J Clin Psychiatry. 2005; 66(6): 750–755CrossRefGoogle ScholarPubMed
Gunnell, D., Saperia, J., Ashby, D.Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005; 330: 385–389CrossRefGoogle ScholarPubMed
Hammad, T. Review and evaluation of clinical data: relationship between psychotropic drugs and pediatric suicidality.www.fda.gov/OHRMS/DOCKETS/AC/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf. 16-8-2004. Ref Type: Electronic Citation.Google Scholar
Hammad, T.A., Laughren, T., Racoosin, J.Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006; 63(3): 332–339CrossRefGoogle ScholarPubMed
Hegerl, U., Gallinat, J., Juckel, G.Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists?. J Affect Disord. 93; 62(1–2–2001): 93–100CrossRefGoogle Scholar
Hegerl, U., Hautzinger, M., Mergl, R., Kohnen, R., Schütze, M., Scheunemann, W., et al.Effects of pharmacotherapy and psychotherapy in depressed primary care patients: a randomised, controlled trial including a patient choice arm. Int J Neuropsychopharmacol. 2010; 13(1): 31–44CrossRefGoogle Scholar
Hegerl, U., Mergl, R.The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences. J Psychopharmacol. 2010; 24(4): 445–448CrossRefGoogle ScholarPubMed
Hegerl, U., Mergl, R., Havers, I., Schmidtke, A., Lehfeld, H., Niklewski, G., et al.Sustainable effects on suicidality were found for the Nuremberg alliance against depression. Eur Arch Psychiatry Clin Neurosci. 52010 401406CrossRefGoogle ScholarPubMed
Hegerl, U., Plattner, A., Moller, H.J.Should combined pharmaco- and psychotherapy be offered to depressed patients? A qualitative review of randomized clinical trials from the 1990s. Eur Arch Psychiatry Clin Neurosci. 2004; 254(2): 99–107CrossRefGoogle ScholarPubMed
Hegerl, U., Seemann, O., Müller-Siecheneder, F.Depression and suicidal behavior more effectively controlled by a team approach. Pilot project to optimize diagnosis and therapy. MMW Fortschr Med. 1999; 141(48): 43–45[Article in German]Google ScholarPubMed
Henkel, V., Mergl, R., Allgaier, A.K., Kohnen, R., Möller, H.J., Hegerl, U.Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 2006; 141(1): 89–101CrossRefGoogle ScholarPubMed
Henkel, V., Mergl, R., Kohnen, R., Maier, W., Möller, H.J., Hegerl, U.Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ. 2003; 326(7382): 200–201CrossRefGoogle ScholarPubMed
Henkel, V, Seemüller, F, Obermeier, M, Adli, M, Bauer, M, Kronmüller, Ket al. Relationship between baseline severity of depression and antidepressant treatment outcome. Pharmacopsychiatry 2011;44(1):27–32.Google ScholarPubMed
Henkel, V., Seemuller, F., Obermeier, M., Adli, M., Bauer, M., Mundt, C., et al.Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord. 2009; 115(3): 439–449CrossRefGoogle Scholar
Hirschfeld, R.M., Montgomery, S.A., Aguglia, E., Amore, M., Delgado, P.L., Gastpar, M., et al.Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002; 63(9): 826–837CrossRefGoogle ScholarPubMed
Holsboer, F., Ising, M.Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008; 583: 350–357CrossRefGoogle ScholarPubMed
Horder, J, Matthews, P, Waldmann, R. Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacol 2010, [Epub ahead of print].CrossRefGoogle Scholar
Höschl, C., Svestka, J.Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev Neurother. 2008; 8(4): 537–552CrossRefGoogle ScholarPubMed
Huf, W, Kalcher, K, Pail, G, Friedrich, ME, Filzmoser, P, Kasper, S. Meta-Analysis: fact or fiction? How to interpret meta-analyses. World J Biol Psychiatry 2011;12(3):188–200.CrossRefGoogle ScholarPubMed
Isacsson, G.Suicide prevention - a medical breakthrough?. Acta Psychiatr Scand. 2000; 102: 113–117CrossRefGoogle ScholarPubMed
Kahn, A., Khan, S.Placebo response in depression: a perspective for clinical practice. Psychopharmacol Bull. 2008; 41(3): 91–98Google Scholar
Kahn, R.S., Fleischhacker, W.W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I.P., et al.Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008; 371(9618): 1085–1097CrossRefGoogle ScholarPubMed
Karasu, T.B., Gelenberg, A., Merriam, A., Wang, P.American Psychiatric Association Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 157 2000 145Google Scholar
Kasper, S., Hamon, M.Agomelatine, a new antidepressant with an innovative mechanism of action - an overview on its preclinical and clinical development program. World J Biol Psychiatry. 2009; 10: 117–126CrossRefGoogle Scholar
Kasper, S., Montgomery, S.A., Möller, H.J., van Oers, H.J.J., Schutte, A.J., Vrijland, P., et al.Longitudinal analysis of the suicidal behavior risk in placebo-controlled studies of mirtazapine in major depressive disorder. World J Biol Psychiatry. 2010; 11: 36–44CrossRefGoogle Scholar
Kasper, S., Sacher, J., Klein, N., Mossaheb, N., Attarbaschi-Steiner, T., Lanzenberger, R., et al.Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol. 2009; 24(3): 119–125CrossRefGoogle ScholarPubMed
Kato, T.Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci. 2007; 61(1): 3–19CrossRefGoogle ScholarPubMed
Katon, W., Robinson, P., von Korff, M., Lin, E., Bush, T., Ludman, E., et al.A mutlifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry. 1996; 53(10): 924–932CrossRefGoogle ScholarPubMed
Keller, M.B.Rationale and options for the long-term treatment of depression. Hum Psychopharmacol. 17Suppl1 2002 S43S46CrossRefGoogle ScholarPubMed
Keller, M.B., Gelenberg, A.J., Hirschfeld, R.M., Rush, A.J., Thase, M.E., Kocsis, J.H., et al.The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry. 1998; 59(11): 598–607CrossRefGoogle ScholarPubMed
Keller, M.B., McCullough, J.P., Klein, D.N., Arnow, B., Dunner, D.L., Gelenberg, A.J., et al.A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000; 342(20): 1462–1470CrossRefGoogle ScholarPubMed
Keller, M.B., Trivedi, M.H., Thase, M.E., Shelton, R.C., Kornstein, S.G., Nemeroff, C.B., et al.The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007; 68(8): 1246–1256CrossRefGoogle ScholarPubMed
Kelsey, J.E., Entsuah, R.Abstract P. 4. W. 031. Neuropsychopharmacol. 5Suppl. 12002 S207[Ref Type: Abstract]Google Scholar
Kessing, L.V.Severity of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Br J Psychiatry. 2004; 184: 153–156CrossRefGoogle ScholarPubMed
Khan, A., Detke, M., Khan, S.R., Mallinckrodt, C.Placebo response and antidepressant clinical trial outcome. J Psychiatr Res. 2003; 191(4): 211–218Google ScholarPubMed
Khan, A., Khan, S.Placebo response in depression: a perspective for clinical practice. Psychopharmacol Bull. 2008; 41(3): 91–98Google ScholarPubMed
Khan, A., Leventhal, R.M., Khan, S.R., Brown, W.A.Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002; 22(1): 40–45CrossRefGoogle ScholarPubMed
Kirsch, I., Deacon, B.J., Huedo-Medina, T.B., Scoboria, A., Moore, T.J., Johnson, B.T.Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 522008 e45CrossRefGoogle ScholarPubMed
Kirsch, I, Moore, TJ, Scoboria, A, Nicholls, S. The emperor's new drugs: an analyses of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat 2002;23:5.Google Scholar
Klein, DF. Listening to meta-analysis but hearing bias. Prev Treat 1, Article 0006c, posted June 26, 1998. http://journals.apa.org/prevention/volume1/pre0010006c.html. 1998. [Ref Type: Electronic Citation].CrossRefGoogle Scholar
Kocsis, J.H., Leon, A.C., Markowitz, J.C., Manber, R., Arnow, B., Klein, D.N., et al.Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry. 2009; 70(3): 354–361CrossRefGoogle ScholarPubMed
Koran, L.M., Gelenberg, A.J., Kornstein, S.G., Howland, R.H., Friedman, R.A., DeBattista, C., et al.Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord. 2001; 65(1): 27–36CrossRefGoogle ScholarPubMed
Lam, R.W., Hossie, H., Solomons, K., Yatham, L.N.Citalopram and Bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004; 65(3): 337–340CrossRefGoogle ScholarPubMed
Laux, G., Baumann, P., Hiemke, C.TDM group of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie. Therapeutic drug monitoring of antidepressants - clinical aspects. J Neural Transm Suppl. 2007; 72: 261–267CrossRefGoogle Scholar
Lépine, J.P., Caillard, V., Bisserbe, J.C., Troy, S., Hotton, J.M., Boyer, P.A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry. 2004; 161(5): 836–842CrossRefGoogle ScholarPubMed
Lépine, J.P., Gastpar, M., Mendlewicz, J., Tylee, A.Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol. 1997; 12(1): 19–29CrossRefGoogle Scholar
Lepola, U., Wade, A., Andersen, H.F.Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol. 2004; 19(3): 149–155CrossRefGoogle ScholarPubMed
Lerer, B., Macciardi, F.Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol. 2002; 5(3): 255–275CrossRefGoogle ScholarPubMed
Lichtenberg, P., Belmaker, R.H.Subtyping major depressive disorder. Psychother Psychosom. 2010; 79: 131–135CrossRefGoogle ScholarPubMed
Llorca, P.M., Azorin, J.M., Despiegel, N., Verpillat, P.Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract. 2005; 59(3): 268–275CrossRefGoogle ScholarPubMed
Lopez, A.D., Murray, C.J.L.The global burden of disease, 1990–2020. Nat Med. 1998; 4(11): 1241–1243CrossRefGoogle ScholarPubMed
Lyness, J.M., Heo, M., Datto, C.J., Ten Have, T.R., Katz, I.R., Drayer, R., et al.Outcomes of minor and subsyndromal depression among elderly patients in primary care settings. Ann Int Med. 2006; 144(7): 496–504CrossRefGoogle ScholarPubMed
Maginn, S., Boardman, A.P., Craig, T.K., Haddad, M., Heath, G., Stott, J.The detection of psychological problems by General Practitioners - influence of ethnicity and other demographic variables. Soc Psychiatry Psychiatr Epidemiol. 2004; 39(6): 464–471CrossRefGoogle ScholarPubMed
Maier, W., Möller, H.J.Meta-analyses: a method to maximise the evidence from clinical studies?. Eur Arch Psychiatry Clin Neurosci. 2010; 260(1): 17–23CrossRefGoogle ScholarPubMed
Mallinckrodt, C.H., Prakash, A., Houston, J.P., Swindle, R., Detke, M.J., Fava, M.Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology. 73; 56(2–3–2007): 73–85CrossRefGoogle Scholar
Melander, H., Salmonson, T., Abadie, E., Zwieten-Boot, B.A regulatory Apologia - a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol. 2008; 18(9): 623–627CrossRefGoogle ScholarPubMed
Mitchell, A.J., Vaze, A., Rao, S.Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009; 374(9690): 609–619CrossRefGoogle ScholarPubMed
Möller, H.J.Antidepressants - do they decrease or increase suicidality?. Pharmacopsychiatry. 1992; 25: 249–253CrossRefGoogle ScholarPubMed
Möller, H.J.Attempted suicide: efficacy of different aftercare strategies. Int Clin Psychopharmacol. 6Suppl 6 1992 5869CrossRefGoogle ScholarPubMed
Möller, H.J., Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatrica Scandinavica Supplementum. 4182003 7380CrossRefGoogle ScholarPubMed
Möller, H.J.Evidence for beneficial effects of antidepressants on suicidality in depressive patients: A systematic review. Eur Arch Psychiatry Clin Neurosci. 2006; 256(6): 329–343[Ref Type: Journal (Full)]CrossRefGoogle ScholarPubMed
Möller, H.J.Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2006; 256(8): 476–496CrossRefGoogle ScholarPubMed
Möller, H.J.Is the identification of the core symptoms of depression clinically relevant?. Medicographia. 2008; 30(1): 3–8Google Scholar
Möller, H.J.Is there a need for a new psychiatric classification at the current state of knowledge?. World J Biol Psychiatry. 2008; 9(2): 82–85CrossRefGoogle Scholar
Möller, H.J.Isn’t the efficacy of antidepressants clinically relevant?. A critical comment on the results of the metaanalysis by Kirsch et al.. Eur Arch Psychiatry Clin Neurosci. 2008; 258(8): 451–455CrossRefGoogle ScholarPubMed
Möller, H.JOutcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. World J Biol Psychiatry. 2008; 9(2): 102–114CrossRefGoogle ScholarPubMed
Möller, H.J.Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. World J Biol Psychiatry. 2009; 10(3): 180–195CrossRefGoogle Scholar
Möller, H.J.Is evidence sufficient for evidence-based medicine?. Eur Arch Psychiatry Clin Neurosci. 2009; 259(Suppl. 2): S167–S172CrossRefGoogle ScholarPubMed
Möller, H.J.Pharmacological and biological treatment of suicidal individuals. Wasserman, D.Wasserman, C.Oxford Textbook of Suicidology and Suicide Prevention. A Global Perspective. New York: Oxford University; 2009 395–405[Press]Google Scholar
Möller, H.J.Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry. 2009; 10(1): 6–26CrossRefGoogle ScholarPubMed
Möller, H.J., Baldwin, D.S., Goodwin, G., Kasper, S., Okasha, A., Stein, D.J., et al.Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci. 2008; 258(Suppl. 3): 3–23CrossRefGoogle ScholarPubMed
Möller, H.J., Broich, K.Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. Eur Arch Psychiatry Clin Neurosci. 2010; 260(1): 3–16CrossRefGoogle ScholarPubMed
Möller, H.J., Fischer, G., von Zerssen, D.Prediction of therapeutic response in acute treatment with antidepressants. Results of an empirical study involving 159 endogenous depressive inpatients. Eur Arch Psychiatry Neurol Sci. 1987; 236: 349–357CrossRefGoogle ScholarPubMed
Möller HJ, Henkel V. What are the most effective diagnostic and therapeutic strategies for the management of depression in specialist care? World Health Organisation http://www.who.dk/Document/E86602.pdf. 2005[Ref Type: Electronic Citation].Google Scholar
Möller, H.J., Maier, W.Evidence-based medicine in psychopharmacotherpy: possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci. 2010; 260(1): 25–39CrossRefGoogle ScholarPubMed
Möller, H.J., Rujescu, D.Pharmacogenetics - genomics and personalized psychiatry. Eur Psychiatry. 2010; 25: 291–293CrossRefGoogle ScholarPubMed
Moncrieff, J., Kirsch, I.Efficacy of antidepressants in adults. BMJ. 2005; 331(7509): 155–157CrossRefGoogle ScholarPubMed
Moncrieff, J, Wessely, S, Hardy, R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev CD003012 2004;(1).CrossRefGoogle Scholar
Montano, C.B.Recognition and treatment of depression in a primary care setting. J Clin Psychiatry. 55 (Suppl)1994 1837Google Scholar
Montgomery, S.A., Andersen, H.F.Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol. 2006; 21(5): 297–309CrossRefGoogle ScholarPubMed
Montgomery, S.A., Baldwin, D.S., Blier, P., Fineberg, N.A., Kasper, S., Lader, M., et al.Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol. 2007; 22(6): 323–329CrossRefGoogle Scholar
Montgomery, S.A., Kasper, S.Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol. 2007; 22(5): 283–291CrossRefGoogle ScholarPubMed
Montgomery, S.A., Möller, H.J.Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. Int Clin Psychopharmacol. 2009; 24(3): 111–118CrossRefGoogle ScholarPubMed
National Collaborating Centre for Mental Health Depression in adults (update); depression: the treatment and management of depression in adults. London: National Institute for Health and Clinical Excellence; 2009Google Scholar
National Institute for Clinical Excellence (NICE) Depression: management of depression in primary and secondary care. Clinical practice guideline No 23. London: National Institute for Clinical Excellence; 2004Google Scholar
Nelson, J.C., Papakostas, G.I.Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009; 166(9): 980–991CrossRefGoogle ScholarPubMed
Papakostas, G.I.Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009; 70(Suppl. 6): 16–25CrossRefGoogle ScholarPubMed
Papakostas, G.I., Charles, D., Fava, M.Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 2010; 11(2): 300–307CrossRefGoogle ScholarPubMed
Papakostas, G.I., Shelton, R.C., Smith, J., Fava, M.Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007; 68: 826–831CrossRefGoogle ScholarPubMed
Papakostas, G.I., Thase, M.E., Fava, M., Nelson, J.C., Shelton, R.C.Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007; 62(11): 1217–1227CrossRefGoogle Scholar
Parker, G.Classifying depression: should paradigms lost be regained?. Am J Psychiatry. 2000; 157(8): 1195–1203CrossRefGoogle ScholarPubMed
Parker, G.Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand. 2002; 106(3): 168–170CrossRefGoogle ScholarPubMed
Paykel, E.S.Cognitive therapy in relapse prevention in depression. Int J Neuropsychopharmacol. 2007; 10(1): 131–136CrossRefGoogle ScholarPubMed
Paykel, E.S., Freeling, P., Hollyman, J.A.Are tricyclic depressants useful for mild depression? A placebo-controlled trial. Pharmacopsychiatry. 1988; 21(1): 15–18CrossRefGoogle Scholar
Paykel, E.S., Scott, J., Cornwall, P.L., Abbott, R., Crane, C., Pope, M., et al.Duration of relapse prevention after cognitive therapy in residual depression: a follow-up of controlled trial. Psychol Med. 2005; 35: 59–68CrossRefGoogle ScholarPubMed
Paykel, E.S., Scott, J., Teasdale, J.D., Johnson, A.L., Garland, A., Moore, R., et al.Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry. 1999; 56(9): 829–835CrossRefGoogle ScholarPubMed
Perlis, R.H., Purcell, S., Fava, M., Fagerness, J., Rush, A.J., Trivedi, M.H., et al.Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry. 2007; 64: 689–697CrossRefGoogle ScholarPubMed
Pigott, H.E., Leventhal, A.M., Alter, G.S., Boren, J.J.Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom. 2010; 79: 267–279CrossRefGoogle ScholarPubMed
Racagni, G., Popoli, M.Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci. 2008; 10(4): 385–400Google ScholarPubMed
Reynolds, C.F. III, Dew, M.A., Pollock, B.G., Mulsant, B.H., Frank, E., Miller, M.D., et al.Maintenance treatment of major depression in old age. N Engl J Med. 2006; 354(11): 1130–1138CrossRefGoogle ScholarPubMed
Rising, K., Bacchetti, P., Bero, L.Reporting bias in drug trials submitted to the Food and Drug Administration: a review of publication and presentation. PLoS Med. 5112008 e217CrossRefGoogle ScholarPubMed
Rix, S., Paykel, E.S., Lelliott, P., Tylee, A., Freeling, P., Gask, L., et al.Impact of a national campaign on GP education: an evaluation of the Defeat Depression Campaign. Br J Gen Pract. 1999; 49(439): 99–102Google ScholarPubMed
Rush, A.J.STAR*D: what have we learned?. Am J Psychiatry. 2007; 164(2): 201–204CrossRefGoogle ScholarPubMed
Rush, A.J., Koran, L.M., Keller, M.B., Markowitz, J.C., Harrison, W.M., Miceli, R.J., et al.The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry. 1998; 59(11): 589–597CrossRefGoogle ScholarPubMed
Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., et al.Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163: 1905–1917CrossRefGoogle ScholarPubMed
Rutz, W., Von Knorring, L., Walinder, J., Wistedt, B.Effect of an educational program for general practitioners on Gotland on the pattern of prescription of psychotropic drugs. Acta Psychiatr Scand. 1990; 82: 399–403CrossRefGoogle ScholarPubMed
Sanchez, C., Bogeso, K.P., Ebert, B., Reines, E.H., Braestrup, C.Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl). 2004; 174(2): 163–176CrossRefGoogle ScholarPubMed
Schaub, A., Roth, E., Goldmann, U.Kognitiv-Psychoedukative Therapie zur Bewältigung von Depressionen: Ein Therapiemanual. Göttingen: Hogrefe; 2006Google Scholar
Schechter, L.E., Ring, R.H., Beyer, C.E., Hughes, Z.A., Khawaja, X., Malberg, J.E., et al.Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx. 2005; 2(4): 590–611CrossRefGoogle ScholarPubMed
Schlaepfer, T.E., George, M.S., Mayberg, G., Mayberg, H.on behalf of the WFSBP Task Force on Brain Stimulation WFSBP Guidelines on Brain Stimulation Treatments in Psychiatry. World J Biol Psychiatry. 11 2010 218CrossRefGoogle Scholar
Schosser, A., Kasper, S.The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol. 2009; 24: 277–288CrossRefGoogle ScholarPubMed
Schramm, E., Schneider, D., Zobel, I., van Calker, D., Dykierek, P., Kech, S., et al.Efficacy of interpersonal psychotherapy plus pharmacotherapy in chronically depressed inpatients. J Affect Disord. 65; 109(1–2–2008): 65–73CrossRefGoogle Scholar
Seemüller, F, Möller, HJ, Obermeier, M, Bauer, M, Adli, M, Mundt, C, et al. Prediction of response and remission in inpatients with depressive symptoms. J Affect Disord 2011;133(1-2):137–49.Google Scholar
Seemüller, F., Riedel, M., Obermeier, M., Bauer, M., Adli, M., Mundt, C., et al.The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int J Neuropsychopharmacol. 2009; 12(2): 181–189CrossRefGoogle Scholar
Seemüller, F., Riedel, M., Wickelmaier, F., Adli, M., Mundt, C., Marneros, A., et al.Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity. J Affect Disord. 2008; 108(3): 271–278CrossRefGoogle ScholarPubMed
Serretti, A., Cusin, C., Rausch, J.L., Bondy, B., Smeraldi, E.Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. Psychiatry Res. 2006; 145(1): 61–65CrossRefGoogle ScholarPubMed
Serretti, A., Kato, M., De Ronchi, D., Kinoshita, T.Meta-analysis of serotonin transporter gene promotor polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007; 12(3): 247–257CrossRefGoogle Scholar
Seyringer, M.E., Kasper, S.Ranking antidepressants. Lancet. 2009; 373: 1760–1761CrossRefGoogle ScholarPubMed
Sharan, P., Saxena, S.Treatment-resistant depression: clinical significance, concept and management. Natl Med J India. 1998; 11(2): 69–79Google ScholarPubMed
Sheehan, DV, Lecrubier, Y. Mini International Neuropsychiatric Interview (M.I.N.I.). Medical Outcome Systems, Inc. 2005 [Ref Type: Electronic Citation].Google Scholar
Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorin, P., Janavs, J., Weiller, E., et al.The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(Suppl. 20): 22–57Google ScholarPubMed
Simon, G.E., Savarino, J.Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry. 2007; 164(7): 1029–1034CrossRefGoogle ScholarPubMed
Singh, I., Rose, N.Biomarkers in psychiatry. Nature. 2009; 460: 202–207CrossRefGoogle Scholar
Sinyor, M., Levitt, A.J., Cheung, A.H., Schaffer, A., Kiss, A., Dowlati, Y., et al.Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry. 2010; 71(3): 270–279CrossRefGoogle ScholarPubMed
Spitzer, R.L., Endicott, J., Robins, E.Research Diagnostic Criteria (RDC). Biometrics Research. New York: New York State Psychiatric Institute; 1975Google Scholar
Stone, M., Jones, M.L., Levenson, M., Holland, P.C., Hughes, A., Hammad, T.A., et al.Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 339 2009 b2880CrossRefGoogle ScholarPubMed
Stone, MB, Jones, ML. Clinical review: Relationship between antidepressant drugs and suicidality in adults. www.fda.gov/OHRMS/DOCKETS/AC/06/briefing/2006-4272b1-01-FDA.pdf 17-11-2006 [Ref Type: Electronic Citation].Google Scholar
Storosum, J.G., Elferink, A.J., van Zwieten, B.J., van den, B.W., Gersons, B.P., van Strik, R., et al.Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol. 2001; 11(2): 173–180CrossRefGoogle ScholarPubMed
Sullivan, P.F., Neale, M.C., Kendler, K.S.Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000; 157(10): 1552–1562CrossRefGoogle ScholarPubMed
Swinkels, J.A., de Jonghe, F.Safety of antidepressants. Int Clin Psychopharmacol. 1995; 9(Suppl. 4): 19–25CrossRefGoogle ScholarPubMed
Szegedi, A., Jansen, W.T., van Willigenburg, A.P., van der, M.E., Stassen, H.H., Thase, M.E.Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009; 70(3): 344–353CrossRefGoogle ScholarPubMed
Tadic, A., Muller, M.J., Rujescu, D., Kohnen, R., Stassen, H.H., Dahmen, N., et al.The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet. 2007; 144B(3): 325–331CrossRefGoogle ScholarPubMed
Teicher, M.H., Glod, C.A., Cole, J.O.Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety. 1993; 8(3): 186–212CrossRefGoogle ScholarPubMed
Thase, M.E., Entsuah, A.R., Rudolph, R.L.Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001; 178: 234–241CrossRefGoogle ScholarPubMed
Thase, M.E., Pritchett, Y.L., Ossanna, M.J., Swindle, R.W., Xu, J., Detke, M.J.Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol. 2007; 27(6): 672–676CrossRefGoogle ScholarPubMed
Thase, M.E., Rush, A.J., Howland, R.H., Kornstein, S.G., Kocsis, J.H., Gelenberg, A.J., et al.Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002; 59(3): 233–239CrossRefGoogle ScholarPubMed
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Tanskanen, A., Haukka, J.Antidepressants and risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry. 2006; 63: 1353–1367CrossRefGoogle Scholar
Toprac, M.G., Dennehy, E.B., Carmody, T.J., Crismon, M.L., Miller, A.L., Trivedi, M.H., et al.Implementation of the Texas Medication Algorithm Project patient and family education program. J Clin Psychiatry. 2006; 67(9): 1362–1372CrossRefGoogle ScholarPubMed
Trindade, E., Menon, D., Topfer, L.A., Coloma, C.Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ. 1998; 159(10): 1245–1252Google ScholarPubMed
Trivedi, M.H., Rush, A.J., Crismon, M.L., Kashner, T.M., Toprac, M.G., Carmody, T.J., et al.Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry. 2004; 61(7): 669–680CrossRefGoogle ScholarPubMed
Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163(1): 28–40CrossRefGoogle ScholarPubMed
Turner, E.H., Matthews, A.M., Linardatos, E., Tell, R.A., Rosenthal, R.Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358(3): 252–260CrossRefGoogle ScholarPubMed
U.S. Food and Drug Administration (FDA). Suicidality in children and adolescents being treated with antidepressant medications. http://www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm. 2004 [Ref Type: Internet Communication].Google Scholar
U.S. Food and Drug Administration (FDA). Suicidality in children and adolescents being treated with antidepressant medications. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096273.htm. 2007 [Ref Type: Internet Communication].Google Scholar
Uhr, M., Tontsch, A., Namendorf, C., Ripke, S., Lucae, S., Ising, M., et al.Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008; 57(2): 203–209CrossRefGoogle ScholarPubMed
Ustün, T.B., Sartorius, N.Mental illness - General Health Care: an international study. Chichester: Wiley; 1995Google Scholar
Vaiva, G., Vaiva, G., Ducrocq, F., Meyer, P., Mathieu, D., Philippe, A., et al.Effect of telephone contact on further suicide attempts in patients discharged from an emergency department: randomised controlled study. BMJ 33275522006 12411245CrossRefGoogle ScholarPubMed
Valenstein, M., McCarthy, J.F., Austin, K.L., Greden, J.F., Young, E.A., Blow, F.C.What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 16372006 12191225CrossRefGoogle ScholarPubMed
Volz, H.P., Baghai, T.C., Möller, H.J.Drug treatment of depression in the 2000s - an overview of achievements in the last ten years and future possibilities. World J Biol Psychiatry 742006 198222Google Scholar
Wade, A., Andersen, H.F.The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 22112006 21012110CrossRefGoogle ScholarPubMed
Wade, A.G., Schlaepfer, T.E., Andersen, H.F., Kilts, C.D.Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). J Psychiatr Res 2009; 43: 568–575CrossRefGoogle ScholarPubMed
Wade, A.G., Toumi, I., Hemels, M.E.H.A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2142005 631641CrossRefGoogle ScholarPubMed
Weinberger, M.I., Sirey, J.A., Bruce, M.L., Heo, M., Papademetriou, E., Meyers, B.S.Predictors of major depression six months after admission for outpatient treatment. Psychiatr Serv 59102008 12111215CrossRefGoogle ScholarPubMed
Williams WJr, , Barrett, J., Oxman, T., Frank, E., Katon, W., Sullivan, M., et al.Treatment of dysthymia and minor depression in primary care: a randomized controlled trial in older adults. JAMA 2000; 284: 1519–1526CrossRefGoogle Scholar
Wittchen, H.U., Höfler, M., Meister, W.Prevalence and recognition of depressive syndromes in German primary care settings: poorly recognized and treated?. Int Clin Psychopharmacol 1632001 121135CrossRefGoogle ScholarPubMed
Wittchen, H.U., Holsboer, F., Jacobi, F.Met and unmet needs in the management of depressive disorder in the community and primary care: the size and breadth of the problem. J Clin Psychiatry 62Suppl. 262001 2328Google Scholar
Wittchen, H.U., Jacobi, F.Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15: 357–376CrossRefGoogle ScholarPubMed
Wittchen, H.U., Knäuper, B., Kessler, R.C.Lifetime risk of depression. Br J Psychiatry 1994; Suppl. 26: 16–22CrossRefGoogle Scholar
World Health Organization. The global burden of disease: 2004 update. World Health Organisation. 2008. 5-12-2010 [Ref Type: Electronic Citation].Google Scholar
Zobel, A.W., Nickel, T., Kunzel, H.E., Ackl, N., Sonntag, A., Ising, M., et al.Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 3432000 171181CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.